Literature DB >> 3371868

The development of cirrhosis in patients with chronic type B hepatitis: a prospective study.

Y F Liaw1, D I Tai, C M Chu, T J Chen.   

Abstract

The incidence and contributing factors of cirrhosis developing in patients with chronic type B hepatitis were assessed prospectively in 684 clinicopathologically verified patients, of which 509 were HBeAg positive and 175 were anti-HBe positive at entry into the study. During an average follow-up period of 35.3 months, cirrhosis occurred 6 to 64 months after entry in 35 HBeAg-positive and 7 anti-HBe positive patients with a calculated annual incidence of 2.4 and 1.3%, respectively (p greater than 0.05). The incidence increased significantly with the increasing age at entry. Patients who had experienced (a) hepatic decompensation, (b) repeated episodes of severe acute exacerbation (with alpha-fetoprotein greater than 100 ng per ml and/or bridging hepatic necrosis), (c) severe acute exacerbation not accompanied by subsequent HBeAg seroconversion and (d) hepatitis B virus reactivation (particularly those with HBeAg reappearance) were found to develop cirrhosis much more frequently (p less than 0.001). Contrary to general belief, patients who had hepatitis delta virus superinfection and patients with chronic active hepatitis were not particularly prone to develop cirrhosis. We conclude that in addition to age factor, the extent, severity, duration, frequency and etiology of the hepatic lobular alterations are important factors for the development of cirrhosis in patients with chronic type B hepatitis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3371868     DOI: 10.1002/hep.1840080310

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  116 in total

1.  A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B.

Authors:  J You; L Zhuang; B Z Tang; W B Yang; S Y Ding; W Li; R X Wu; H L Zhang; Y M Zhang; S M Yan; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

Review 2.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

3.  Sensitive assay for quantification of hepatitis B virus mutants by use of a minor groove binder probe and peptide nucleic acids.

Authors:  Shuhei Hige; Yoichi Yamamoto; Shigeru Yoshida; Tomoe Kobayashi; Hiromasa Horimoto; Keiko Yamamoto; Takuya Sho; Mitsuteru Natsuizaka; Mitsuru Nakanishi; Makoto Chuma; Masahiro Asaka
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

4.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

5.  Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.

Authors:  Helen Dakin; Morris Sherman; Scott Fung; Carrie Fidler; Anthony Bentley
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

6.  Comparison of the nucleic acid-based crosslinking hybridization assay and the branched DNA signal amplification assay in the quantitative measurement of serum hepatitis B virus DNA.

Authors:  S J Hwang; R H Lu; M L Wood; Y J Wang; F Y Chang; S D Lee
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

7.  Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly.

Authors:  Kazuaki Tejima; Ryota Masuzaki; Hitoshi Ikeda; Haruhiko Yoshida; Ryosuke Tateishi; Yosuke Sugioka; Yukio Kume; Tomoko Okano; Tomomi Iwai; Hiroaki Gotoh; Sachiko Katoh; Atsushi Suzuki; Yukako Koike; Yutaka Yatomi; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2010-03-26       Impact factor: 7.527

Review 8.  Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review.

Authors:  María Buti; Itziar Oyagüez; Virginia Lozano; Miguel A Casado
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

9.  Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma.

Authors:  Myron J Tong; Lawrence M Blatt; Jia-Horng Kao; Jason Tzuying Cheng; William G Corey
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

10.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.